ViroPharma Incorporated (VPHM)

[surf1944]

7:34AM ViroPharma misses by $0.06, misses on revs (VPHM) 13.90 : Reports Q1 (Mar) earnings of $0.26 per share, $0.06 worse than the Thomson Reuters consensus of $0.32; revenues rose 50.5% year/year to $90.6 mln vs the $92.5 mln consensus. ViroPharma is increasing the bottom of its Cinryze net sales guidance range and reiterating our expense guidance for the year 2010. For the year 2010, ViroPharma expects the following: Net Cinryze sales are expected to be $155 to $175 million. Research and development (R&D) and selling, general and administrative (SG&A) expenses, including the impact of SFAS 123R,are expected to be $125 to $140 million. SFAS 123R expenses are expected to be between $10 and $12 million.